UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 08/2020, Volume 159, Issue 2, p. 801
Journal Article
Diabetes (New York, N.Y.), ISSN 0012-1797, 06/2020, Volume 69, Issue Supplement 1, p. 68
Journal Article
The lancet oncology, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1029 - 1035
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Recurrence | Prospective Studies | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Time Factors | Aged, 80 and over | Adult | Female | France | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Proto-Oncogene Proteins c-abl - genetics | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Gene Expression Regulation, Leukemic | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Remission Induction | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Benzamides | Antimitotic agents | Arson | Antineoplastic agents | Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2149 - 2158
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Diabetes. Impaired glucose tolerance | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Metabolic diseases | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Glycated Hemoglobin A - analysis | Triazoles - administration & dosage | Triazoles - adverse effects | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Immunoglobulin Fc Fragments - administration & dosage | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Double-Blind Method | Treatment Outcome | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Pyrazines - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Sitagliptin | Care and treatment | Dosage and administration | Safety and security measures | Comparative analysis | Clinical trials | Hemoglobin | Glycosylation | Diabetes | Product safety | Placebo effect | Index Medicus | Psychosocial Research | Nutrition | Education | Clinical Care
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 01/2017, Volume 35, Issue 3, pp. 298 - 305
Life Sciences & Biomedicine | Oncology | Science & Technology | Predictive Value of Tests | Recurrence | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Patient Selection | Neoplasm, Residual | Molecular Diagnostic Techniques | Time Factors | Antineoplastic Agents - adverse effects | Imatinib Mesylate - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Imatinib Mesylate - administration & dosage | Aged, 80 and over | Adult | Female | France | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Drug Administration Schedule | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Aged | Biomarkers, Tumor - genetics | Index Medicus
Journal Article
American journal of hematology, ISSN 0361-8609, 07/2013, Volume 88, Issue 7, pp. 556 - 559
Life Sciences & Biomedicine | Hematology | Science & Technology | Recurrence | Tretinoin - administration & dosage | Leukemia, Promyelocytic, Acute - pathology | Follow-Up Studies | Humans | Middle Aged | Risk Factors | Antineoplastic Combined Chemotherapy Protocols | Male | Treatment Outcome | Cytarabine - administration & dosage | Early Termination of Clinical Trials | Female | Daunorubicin - administration & dosage | Leukemia, Promyelocytic, Acute - drug therapy | Evaluation | Care and treatment | Chemotherapy | Daunorubicin | Leukemia | Clinical trials | Tretinoin | Cancer | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9833, pp. 2270 - 2278
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Public health. Hygiene-occupational medicine | Public health. Hygiene | General aspects | Diabetes. Impaired glucose tolerance | Prevention and actions | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Metformin - therapeutic use | Drug Administration Schedule | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Risk Factors | Diabetes Mellitus, Type 2 - prevention & control | Male | Peptides - administration & dosage | Young Adult | Diabetes Mellitus, Type 2 - blood | Analysis of Variance | Hypoglycemic Agents - administration & dosage | Treatment Failure | Adolescent | Aged, 80 and over | Venoms - administration & dosage | Adult | Female | Aged | Sulfonylurea Compounds - administration & dosage | Blood Glucose - metabolism | Glimepiride | Control | Usage | Research | Blood sugar | Exenatide | Automation | Gastrointestinal diseases | Blood pressure | Diabetes | Clinical medicine | Glucose | Pharmaceutical industry | Insulin | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The lancet. Diabetes & endocrinology, ISSN 2213-8587, 11/2017, Volume 5, Issue 11, pp. 864 - 876
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - therapeutic use | Humans | Middle Aged | Body Weight - drug effects | Male | Treatment Outcome | Diabetes Mellitus, Type 1 - drug therapy | Adult | Female | Glucosides - therapeutic use | Drug Therapy, Combination | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Insulin - therapeutic use | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 424 - 430
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Piperazines - administration & dosage | Recurrence | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | France | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Drug Administration Schedule | Pyrimidines - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism | Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 08/2016, Volume 39, Issue 8, pp. 1318 - 1328
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Body Mass Index | Overweight - complications | Body Weight | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Peptides - administration & dosage | Hypoglycemia - prevention & control | Insulin Glargine - administration & dosage | Glucagon-Like Peptide-1 Receptor - metabolism | Hypoglycemic Agents - administration & dosage | Endpoint Determination | Postprandial Period | Female | Aged | Metformin - administration & dosage | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Meals | Glucagon-Like Peptide-1 Receptor - agonists | Type 2 diabetes | Overweight persons | Complications and side effects | Mouthwashes | Dosage and administration | Health aspects | Risk factors | Obesity | Diabetes | Peptides | Hypoglycemia | Insulin | Optimization | Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 12/2009, Volume 32, Issue 12, pp. 2245 - 2250
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Public health. Hygiene-occupational medicine | Public health. Hygiene | Diabetes. Impaired glucose tolerance | Miscellaneous | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Metabolic diseases | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Body Mass Index | Hypoglycemic Agents - therapeutic use | Blood Glucose - analysis | Monitoring, Ambulatory - methods | Glycated Hemoglobin A - metabolism | Humans | Insulin - administration & dosage | Male | Diabetes Mellitus, Type 1 - drug therapy | Dose-Response Relationship, Drug | Blood Glucose Self-Monitoring - methods | Hypoglycemic Agents - administration & dosage | Diabetes Mellitus, Type 1 - blood | Adolescent | Age of Onset | Adult | Female | Insulin Infusion Systems | Blood Glucose - metabolism | Child | Insulin - therapeutic use | Medical research | Care and treatment | Blood sugar monitoring | Blood sugar | Patient monitoring equipment | Medicine, Experimental | Diabetes | Research | Sensors | Insulin | Diabetes therapy | Glucose | Disease management | Patients | Monitoring systems | Index Medicus | Life Sciences | Human health and pathology | Endocrinology and metabolism | Original Research
Journal Article
Cardiovascular diabetology, ISSN 1475-2840, 05/2020, Volume 19, Issue 1, pp. 65 - 65
Journal Article